Aging runs on a small set of interlocking cellular systems that drift out of balance over time. The longevity field works from the idea that those systems can be measured and targeted directly. Regenerative medicine is one of the more concrete tools for doing that.
By Jed Ryan, Founder and CEO · Reviewed by Adas Darinskas, PhD, Chief Science Officer · Published · Last reviewed
The visible signs of aging, like reduced energy, slower recovery, cognitive softening, accumulated weight, and declining mobility, all sit on top of a small number of underlying biological processes. Geroscience has spent two decades cataloguing them, and most cluster under what researchers now call the “hallmarks of aging.”
The cluster we work with covers:
Each of these is a measurable cellular process, and each is something regenerative medicine has at least one direct mechanism to address.
The hallmarks of aging are interrelated, so intervention on one usually affects the others. A useful longevity protocol targets several at once.
Senescent cells stop dividing but don’t die cleanly. They accumulate in aging tissue, secreting a pro-inflammatory cocktail (the SASP) that drives dysfunction in surrounding cells. Many age-related conditions trace back to senescent-cell burden.
Mitochondrial DNA damage accumulates, oxidative phosphorylation efficiency falls, and the cofactors mitochondria need (notably NAD+) deplete with age. Tissue energy capacity drops; recovery slows; everything downstream becomes harder.
The protective caps at the ends of chromosomes shorten with each cell division. Once they reach a critical length, cells stop dividing. Stem cell populations are particularly affected, contributing to the next hallmark.
DNA methylation patterns, the marks that determine which genes are expressed in which cells, lose fidelity over time. Cells start expressing the wrong genes at the wrong times. Epigenetic clocks now measure this drift directly.
Chronic, low-grade systemic inflammation rises with age, partly driven by senescent cells and partly by immune system dysfunction. It accelerates virtually every other hallmark.
The body’s tissue-resident stem cell populations decline in number and activity with age. Repair capacity falls; injuries take longer to heal; degeneration outpaces regeneration.
Standard wellness advice (sleep, nutrition, exercise) addresses these systems indirectly and slowly. Regenerative medicine works on them at the cellular level, with effects measurable in months rather than decades.
Four primary mechanisms do most of the work in longevity protocols.
Systemic infusion of next-generation MSCs supports the body’s declining endogenous stem cell populations. The administered cells contribute paracrine support and, in some tissue contexts, direct engraftment. The net effect is a partial reversal of the stem-cell-exhaustion hallmark.
The MSC secretome carries growth factors, exosomes, and signaling molecules that aging tissue needs but no longer produces in adequate amounts. Tissue function improves measurably across multiple organ systems in published trials, even when no individual cell “heals” anything specific.
MSC therapy doesn’t kill senescent cells directly the way pharmacological senolytics do, but it modulates the immune environment that allows senescent cells to accumulate in the first place. The functional outcome (reduced SASP burden, lower inflammaging) is convergent.
MSCs transfer functional mitochondria to stressed cells. Targeted peptides (MOTS-c, SS-31, 5-Amino-1MQ) and NAD+ precursors restore mitochondrial cofactor pools and signaling. Combined, they address what is arguably the most central hallmark of cellular aging.
Longevity work is iterative. Most patients run protocols at 6–12 month intervals, with biomarker tracking (epigenetic age, inflammatory markers, mitochondrial function) to evaluate response over time.
Longevity protocols are designed individually by our medical team based on baseline biomarkers, age, family history, and existing health context. The four building blocks below are the ones most often deployed.
An advanced class of mesenchymal stem cells with a stress-enduring property. Systemic IV delivery supports declining endogenous stem cell pools, contributes paracrine signaling to aging tissue, and modulates the inflammatory environment that drives inflammaging. The cellular foundation of any serious longevity protocol.
Learn MoreStem-cell-derived nanoparticles that distribute the regenerative cargo systemically. Smaller and more diffusible than the cells themselves, they reach tissue beds (including the brain) that are harder to access with cellular therapy alone. Often layered with MSCs in longevity protocols.
Learn MoreA targeted longevity peptide stack: Epitalon for telomerase support and pineal-axis function; MOTS-c and 5-Amino-1MQ for mitochondrial and metabolic biology; GHK-Cu for tissue and skin regeneration; Cerebrolysin for cognitive support. Stacked selectively per case, and not all patients use all peptides.
Learn MoreNAD+ infusions are foundational in longevity work, delivering mitochondrial cofactor restoration at a concentration no oral supplement matches. Layered with high-dose vitamin C, glutathione, and amino-acid infusions to support the broader metabolic environment in which the cellular work has to operate.
Learn MoreLongevity protocols are typically run as a 1–2 week in-clinic phase followed by an extended at-home peptide cycle, with follow-up rounds at defined intervals as biomarker data accumulates. We track outcomes; we don’t guess at them.
Strong Craft Regen maintains a continuously updated repository of peer-reviewed research on regenerative medicine: the studies, mechanisms, and ongoing investigations that inform every protocol we coordinate.
Explore the Research